Shares of Cybin, Inc. ($CYBN) surged as much as 10% on Monday, reaching their highest level since May, following the ...

Nipocalimab is a fully human monoclonal antibody that blocks FcRn and decreases levels of circulating IgG antibodies.

A clinical trial has shown promising results in treating brain tumours in children using an immune-cell therapy known as ...

Music therapy reduces distress and improves well-being in advanced dementia by meeting unmet needs, enhancing ...

Johnson & Johnson (J&J) has announced that its anti-FcRn antibody nipocalimab has become the first investigational therapy to ...

Johnson & Johnson announced that the U.S. Food and Drug Administration has granted nipocalimab Breakthrough Therapy designation for the ...

Researchers from the Center for Regenerative Medicine (CReM) and the Department of Medicine at Boston Medical Center (BMC) ...

Johnson & Johnson said its nipocalimab treatment for adults living with moderate-to-severe Sjögren's disease has received breakthrough therapy designation from the Food and Drug Administration.

A Seattle biotech company is working on a tweak to gene expression that could shut down hepatitis B (HBV), one of the viruses ...

Research from the College of Medicine provides promising insights into delaying the progression of Alzheimer’s disease for several years after the initial diagnosis. A recent study by researchers at C ...

The groundbreaking new NHS lupus therapy works by genetically modifying cells to enable the body's immune system to recognise ...

A 16-month-old boy from a low-income family in Kolkata receives a rare gene therapy for spinal muscular atrophy free of ...